TCTR20220916001尚未招募不适用
ow dose Cyproterone acetate as an effective androgen lowering agent: a randomized controlled trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- Male
入选标准
- •1.Age between 18 to 40 yr
- •2. never receive any gender affirming hormone therapy before or stop using the hormonal treatment at least 3 months
- •3. no contraindication for GAHT
- •4. willing to participate this study
- •5. can read Thai
排除标准
- •1. underwent gender affirming surgery
- •2. low baseline testosterone (<250 ng/dL)
- •3. History of venous thromboembolism
- •4. Psychological problems
- •5. Thai Language barrier
- •6. Hyperkalemia
- •7. contraindication for GAHR; such as active kidney disease, cancer
研究者
相似试验
终止
不适用
Androcur Non-interventional Study Among Patients With Carcinoma of the ProstateProstate CancerNCT00919022Bayer194
已完成
3 期
Effect of Cyproterone acetate in patients with Benign Prostatic HypertrophyIRCT20181106041572N1Mashhad University of Medical Sciences84
已完成
3 期
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate AdenocarcinomaAdenocarcinoma, ProstateNCT01011751Takeda311
已完成
不适用
Comparison of two therapies for hyperandrogenism in girlsHyperinsulinemic ovarian androgen excessNutritional, Metabolic, EndocrineOvarian dysfunctionISRCTN45546616Hospital Sant Joan de Déu (Spain)46
已完成
不适用
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in EuropeSigns of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and SeborrheaHypersexuality in MenSexual Deviations in MenProstate CancerNCT04925180Bayer600